| 2025-12-01 |
详情>>
内部人交易：
Teo Sow Hang共交易2笔
|
| 2025-10-23 |
详情>>
股本变动：
变动后总股本4656.34万股
|
| 2025-10-23 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.54美元,归母净利润2472.10万美元,同比去年增长3.02%
|
| 2025-10-22 |
财报披露：
美东时间 2025-10-22 盘后发布财报
|
| 2025-07-25 |
详情>>
业绩披露：
2025年中报每股收益0.22美元,归母净利润1048.20万美元,同比去年增长-14.45%
|
| 2025-03-31 |
股东大会：
将于2025-05-21召开股东大会
会议内容 ▼▲
- 1.To elect one new Class II Director and to re-elect two current Class II Directors to serve under the terms and conditions described in the proxy statement until our annual meeting in 2028 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables;
4.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2025-03-31 |
股东大会：
将于2025-05-21召开股东大会
会议内容 ▼▲
- 1.To elect one new Class II Director and to re-elect two current Class II Directors to serve under the terms and conditions described in the proxy statement until our annual meeting in 2028 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables;
4.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2025-02-13 |
详情>>
业绩披露：
2022年年报每股收益0.42美元,归母净利润1945.30万美元,同比去年增长-1.39%
|
| 2025-02-13 |
详情>>
业绩披露：
2024年年报每股收益0.67美元,归母净利润3140.00万美元,同比去年增长-14.38%
|
| 2024-10-24 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.51美元,归母净利润2399.70万美元,同比去年增长-30.4%
|
| 2024-07-25 |
详情>>
业绩披露：
2024年中报每股收益0.26美元,归母净利润1225.20万美元,同比去年增长-51.42%
|
| 2024-07-25 |
详情>>
业绩披露：
2023年中报每股收益0.54美元,归母净利润2521.90万美元,同比去年增长387.04%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益0.07美元,归母净利润322.00万美元,同比去年增长35.69%
|
| 2024-03-19 |
股东大会：
将于2024-05-08召开股东大会
会议内容 ▼▲
- 1.To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables;
4.To approve and resolve the amendment and restatement of the Company’s 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through May 8, 2034;
5.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2024-03-19 |
股东大会：
将于2024-05-08召开股东大会
会议内容 ▼▲
- 1.To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables;
4.To approve and resolve the amendment and restatement of the Company’s 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through May 8, 2034;
5.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2024-02-15 |
详情>>
业绩披露：
2023年年报每股收益0.79美元,归母净利润3667.50万美元,同比去年增长88.53%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.74美元,归母净利润3447.60万美元,同比去年增长171.42%
|
| 2023-04-28 |
股东大会：
将于2023-06-28召开股东大会
会议内容 ▼▲
- 1.To elect one new Class I Director and to re-elect one current Class I Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2026 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2023;
3.To:
(a)approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules, including the compensation tables;
(b)approve the selection of the frequency of shareholder votes on executive compensation, such that the shareholders of the Company be provided an opportunity to approve the compensation philosophy, policies and procedures described in the CD&A, and the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules, including the compensation tables, every:
One year_______
Two years_______
Three years_______
4.To approve and resolve the amendment and restatement of the Company’s 2014 Non-Employee Director Stock Incentive Plan (the “Director Plan”), the principal purpose of which is to extend the term of the Director Plan through June 28, 2033;
5.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2023-04-28 |
股东大会：
将于2023-06-28召开股东大会
会议内容 ▼▲
- 1.To elect one new Class I Director and to re-elect one current Class I Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2026 and until their successors shall have been duly elected and qualified;
2.To ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountants for the year ending December 31, 2023;
3.To:
(a)approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules, including the compensation tables;
(b)approve the selection of the frequency of shareholder votes on executive compensation, such that the shareholders of the Company be provided an opportunity to approve the compensation philosophy, policies and procedures described in the CD&A, and the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules, including the compensation tables, every:
One year_______
Two years_______
Three years_______
4.To approve and resolve the amendment and restatement of the Company’s 2014 Non-Employee Director Stock Incentive Plan (the “Director Plan”), the principal purpose of which is to extend the term of the Director Plan through June 28, 2033;
5.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2023-02-28 |
股东大会：
将于2023-03-29召开股东大会
会议内容 ▼▲
- 1.To consider and, if deemed advisable, to adopt a special resolution of the Core Lab N.V. Shareholders (the “Transaction Proposal”) to approve a series of transactions (the “Transaction”), which will include (i) a resolution to enter into the merger, pursuant to the merger plan (the “Merger Plan”) (in the form attached as Appendix A – Merger Plan to this Proxy Statement/Prospectus), by way of a downstream cross-border merger (the “Merger”) of Core Lab N.V. with and into Core Laboratories Luxembourg S.A., a public limited liability company incorporated under the laws of Luxembourg (“Core Lab Luxembourg”) with Core Lab Luxembourg surviving, such that all assets and liabilities of Core Lab N.V. are transferred to Core Lab Luxembourg by universal succession of title and Core Lab N.V. will cease to exist without going into liquidation, against the issuance of new Core Lab Luxembourg shares, in accordance with an exchange ratio of one Core Lab Luxembourg share for one Core Lab N.V. share, and (ii) as soon as practicable following completion of the Merger, Core Lab Luxembourg migrating out of Luxembourg and domesticating as Core Laboratories Inc. (“Core Lab Delaware”), a Delaware corporation (the “U.S. Redomestication”), as more particularly described in the accompanying proxy statement and prospectus of Core Lab N.V. dated February 28, 2023 (as may be amended, supplemented or otherwise modified from time to time) (the “Proxy Statement/Prospectus”). By casting a vote in favor of the Transaction Proposal, the respective shareholder of Core Lab N.V. agrees to the U.S. Redomestication and furthermore grants a power of attorney (in the form attached as Appendix D – Power of Attorney to this Proxy Statement/Prospectus) to each member of the board of directors of Core Lab Luxembourg (the “Luxembourg Meeting Proxies”) to individually, vote by proxy, the shares of Core Lab N.V. Shareholders in favor of the U.S. Redomestication at an extraordinary general meeting of Core Lab Luxembourg (the “Luxembourg Meeting”) to be held as per the Notice of Extraordinary General Meeting of Core Lab Luxembourg;
2.To consider and, if deemed advisable, to adopt a special resolution of the Core Lab N.V. Shareholders (the “Articles of Amendment Proposal”), to amend the articles of association of Core Lab N.V., as amended, (“Articles of Association”) to include a formula on the basis of which cash compensation to Core Lab N.V. Shareholders who exercise their withdrawal right in connection with the Merger, as referred to in Section 2:333h (1) of the Dutch Civil Code, can be readily determined (in the form attached as Appendix E – Deed of Amendment of the Articles to this Proxy Statement/Prospectus) and to adopt a special resolution to grant a Power of Attorney to each notarial employee of HVG Law LLP jointly as well as severally to execute and sign the Deed of Amendment of the Articles.
|
| 2023-02-28 |
股东大会：
将于2023-03-29召开股东大会
会议内容 ▼▲
- 1.To consider and, if deemed advisable, to adopt a special resolution of the Core Lab N.V. Shareholders (the “Transaction Proposal”) to approve a series of transactions (the “Transaction”), which will include (i) a resolution to enter into the merger, pursuant to the merger plan (the “Merger Plan”) (in the form attached as Appendix A – Merger Plan to this Proxy Statement/Prospectus), by way of a downstream cross-border merger (the “Merger”) of Core Lab N.V. with and into Core Laboratories Luxembourg S.A., a public limited liability company incorporated under the laws of Luxembourg (“Core Lab Luxembourg”) with Core Lab Luxembourg surviving, such that all assets and liabilities of Core Lab N.V. are transferred to Core Lab Luxembourg by universal succession of title and Core Lab N.V. will cease to exist without going into liquidation, against the issuance of new Core Lab Luxembourg shares, in accordance with an exchange ratio of one Core Lab Luxembourg share for one Core Lab N.V. share, and (ii) as soon as practicable following completion of the Merger, Core Lab Luxembourg migrating out of Luxembourg and domesticating as Core Laboratories Inc. (“Core Lab Delaware”), a Delaware corporation (the “U.S. Redomestication”), as more particularly described in the accompanying proxy statement and prospectus of Core Lab N.V. dated February 28, 2023 (as may be amended, supplemented or otherwise modified from time to time) (the “Proxy Statement/Prospectus”). By casting a vote in favor of the Transaction Proposal, the respective shareholder of Core Lab N.V. agrees to the U.S. Redomestication and furthermore grants a power of attorney (in the form attached as Appendix D – Power of Attorney to this Proxy Statement/Prospectus) to each member of the board of directors of Core Lab Luxembourg (the “Luxembourg Meeting Proxies”) to individually, vote by proxy, the shares of Core Lab N.V. Shareholders in favor of the U.S. Redomestication at an extraordinary general meeting of Core Lab Luxembourg (the “Luxembourg Meeting”) to be held as per the Notice of Extraordinary General Meeting of Core Lab Luxembourg;
2.To consider and, if deemed advisable, to adopt a special resolution of the Core Lab N.V. Shareholders (the “Articles of Amendment Proposal”), to amend the articles of association of Core Lab N.V., as amended, (“Articles of Association”) to include a formula on the basis of which cash compensation to Core Lab N.V. Shareholders who exercise their withdrawal right in connection with the Merger, as referred to in Section 2:333h (1) of the Dutch Civil Code, can be readily determined (in the form attached as Appendix E – Deed of Amendment of the Articles to this Proxy Statement/Prospectus) and to adopt a special resolution to grant a Power of Attorney to each notarial employee of HVG Law LLP jointly as well as severally to execute and sign the Deed of Amendment of the Articles.
|
| 2022-03-22 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.To elect one new Class II Supervisory Director and to re-elect two current Class II Supervisory Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2025 and until their successors shall have been duly elected and qualified;
2.To appoint KPMG, including its U.S. and Dutch affiliates (collectively, “KPMG”), as the Company's independent registered public accountants for the year ending December 31, 2022;
3.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2021, following a discussion of our Dutch Report of the Management Board for that same period;
4.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 19, 2022;
5.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 19, 2023, and such repurchased shares may be used for any legal purpose;
6.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2023;
7.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2023;
8.To:(a)approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission's compensation disclosure rules, including the compensation tables;(b)cast a favorable advisory vote on the remuneration report referred to in Section 2:135b of the Dutch Civil Code for the fiscal year ended December 31, 2021;
9.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-05-19召开股东大会
会议内容 ▼▲
- 1.To elect one new Class III Supervisory Director and to re-elect one current Class III Supervisory Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2024 and until their successors shall have been duly elected and qualified;
2.To appoint KPMG, including its U.S. and Dutch affiliates (collectively, "KPMG") as the Company's independent registered public accountants for the year ending December 31, 2021;
3.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2020, following a discussion of our Dutch Report of the Management Board for that same period;
4.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 19, 2021;
5.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 19, 2022, and such repurchased shares may be used for any legal purpose;
6.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2022;
7.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2022;
8.1.approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis ("CD&A"), and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission's compensation disclosure rules, including the compensation tables;
8.2.cast a favorable advisory vote on the remuneration report referred to in Section 2:135b of the Dutch Civil Code for the fiscal year ended December 31, 2020;
9.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2020-03-20 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.To elect two Class I Supervisory Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2023 and until their successors shall have been duly elected and qualified;
2.To appoint KPMG, including its U.S. and Dutch affiliates (collectively, "KPMG") as the Company's independent registered public accountants for the year ending December 31, 2020;
3.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2019, following a discussion of our Dutch Report of the Management Board for that same period;
4.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 20, 2020;
5.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 20, 2021, and such repurchased shares may be used for any legal purpose;
6.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021;
7.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021;
8.To:(a)approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis ("CD&A"), and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission's compensation disclosure rules, including the compensation tables;
(b)cast a favorable advisory vote on the remuneration report referred to in Section 2:135b of the Dutch Civil Code for the fiscal year ended December 31, 2019;
(c)adopt the remuneration policy for the Management Board and the Supervisory Board in line with new Dutch legal requirements;
9.To approve and resolve the amendment and restatement of the Core Laboratories N.V. 2014 Long-Term Incentive Plan (the “LTIP”), the principal purposes of which are to increase the number of shares authorized for issuance thereunder, to extend the term of the LTIP through May 20, 2030, and for other purposes;
10.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2020-01-14 |
除权日：
美东时间 2020-01-23 每股派息0.25美元
|
| 2019-10-08 |
除权日：
美东时间 2019-10-17 每股派息0.55美元
|
| 2019-07-12 |
除权日：
美东时间 2019-07-19 每股派息0.55美元
|
| 2019-04-16 |
除权日：
美东时间 2019-04-25 每股派息0.55美元
|
| 2019-03-20 |
股东大会：
将于2019-05-23召开股东大会
会议内容 ▼▲
- 1.To re-elect two Class II Supervisory Directors and to elect one new Class II Supervisory Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2022 and until their successors shall have been duly elected and qualified;
2.To appoint KPMG, including its U.S. and Dutch affiliates (collectively, "KPMG") as the Company's independent registered public accountants for the year ending December 31, 2019;
3.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2018, following a discussion of our Dutch Report of the Management Board for that same period;
4.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 23, 2019;
5.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 23, 2020, and such repurchased shares may be used for any legal purpose;
6.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 23, 2020;
7.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 23, 2020;
8.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Disclosure and Analysis ("CD&A"), and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission's compensation disclosure rules, including the compensation tables;
9.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2019-01-15 |
除权日：
美东时间 2019-01-24 每股派息0.55美元
|
| 2018-10-09 |
除权日：
美东时间 2018-10-18 每股派息0.55美元
|
| 2018-07-13 |
除权日：
美东时间 2018-07-20 每股派息0.55美元
|
| 2018-04-17 |
除权日：
美东时间 2018-04-26 每股派息0.55美元
|
| 2018-03-23 |
股东大会：
将于2018-05-24召开股东大会
会议内容 ▼▲
- 1.To re-elect one Class III Supervisory Director and to elect one new Class III Supervisory Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2021 and until their successors shall have been duly elected and qualified;
2.To appoint KPMG, including its U.S. and Dutch affiliates, (collectively, "KPMG") as Core Laboratories N.V.'s (the "Company") independent registered public accountants for the year ending December 31, 2018;
3.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2017, following a discussion of our Dutch Report of the Management Board for that same period;
4.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 24, 2018;
5.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 24, 2019, and such repurchased shares may be used for any legal purpose;
6.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 24, 2019;
7.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 24, 2019;
8.To approve, on an advisory basis, the compensation of our executive officers as described in the Compensation Discussion and Analysis ("CD&A") section of the accompanying proxy statement and the selection of the frequency of shareholder votes on executive compensation as separate voting items:
a.the shareholders approve the compensation philosophy, policies and procedures described in the CD&A, and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the United States Securities and Exchange Commission's (the "SEC") compensation disclosure rules, including the compensation tables;
b.the shareholders of the Company be provided an opportunity to approve the compensation philosophy, policies and procedures described in the CD&A, and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the SEC's compensation disclosure rules, including the compensation tables every:
9.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2018-01-16 |
除权日：
美东时间 2018-01-25 每股派息0.55美元
|
| 2017-10-10 |
除权日：
美东时间 2017-10-19 每股派息0.55美元
|
| 2017-07-06 |
除权日：
美东时间 2017-07-13 每股派息0.55美元
|
| 2017-04-18 |
除权日：
美东时间 2017-04-26 每股派息0.55美元
|
| 2017-03-24 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1.To re-elect two Class I Supervisory Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2020 and until their successors shall have been duly elected and qualified;
2.To amend Article 20, paragraph 5(ii), of our Articles of Association to allow for any future amendments to the Articles of Association which are proposed by the board of management and which proposal is approved by the board of supervisory directors, to be passed with an absolute majority of votes cast, without regard to the number of shares represented at the meeting;
3.To appoint KPMG, including its U.S. and Dutch affiliates, (collectively, "KPMG") as Core Laboratories N.V.'s (the "Company") independent registered public accountants for the year ending December 31, 2017;
4.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis ("CD&A section"), and the compensation of the Company's named executive officers as disclosed pursuant to the Security and Exchange Commission's compensation disclosure rules, including the compensation tables;
5.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2016, following a discussion of our Dutch Report of the Management Board for that same period;
6.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 18, 2017;
7.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 18, 2018, and such repurchased shares may be used for any legal purpose;
8.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 18, 2018;
9.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 18, 2018; 10.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2017-01-10 |
除权日：
美东时间 2017-01-18 每股派息0.55美元
|
| 2016-10-11 |
除权日：
美东时间 2016-10-19 每股派息0.55美元
|
| 2016-07-07 |
除权日：
美东时间 2016-07-14 每股派息0.55美元
|
| 2016-04-14 |
除权日：
美东时间 2016-05-02 每股派息0.55美元
|
| 2016-03-23 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1.To re-elect two Class II Supervisory Directors and to elect one new Class II Supervisory Director to serve under the terms and conditions described within the proxy statement until our annual meeting in 2019 and until their successors shall have been duly elected and qualified;
2.To elect a new additional Class I Supervisory Director to serve until our annual meeting in 2020, pending approval and implementation of agenda item no. 3 below, or in the event agenda item no. 3 is not approved, to serve as a Class II Supervisory Director until our annual meeting in 2019 and until a successor shall have been duly elected and qualified, in each case under the terms and conditions described within the proxy statement and with effect from July 1, 2016;
3.To amend article 16, sub-article 15 of our articles of association to read in its entirety, as follows (the following being an English translation of the official Dutch text):
"The supervisory board shall institute a retirement rota in order to preclude, to the extent possible, a situation in which a substantial number of supervisory directors retire simultaneously or the composition of the supervisory board is not properly constituted in the opinion of the supervisory board. A supervisory director may be appointed for a term, not to exceed four years, consistent with this retirement rota and as necessary in order to accomplish these goals. With due observance of the preceding sentences, each supervisory director shall be eligible for immediate re-appointment. The rota shall be made available and shall, in any event, be put on the Company's website. A member of the supervisory board shall be re-appointed only after careful consideration.";
4.To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis ("CD&A section"), and the compensation of Core Laboratories N.V.'s named executive officers as disclosed pursuant to the Security and Exchange Commission's compensation disclosure rules, including the compensation tables;
5.To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2015, following a discussion of our Dutch Report of the Management Board for that same period;
6.To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 19, 2016;
7.To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 19, 2017, and such repurchased shares may be used for any legal purpose;
8.To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2017;
9.To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 19, 2017;
10.To convene a discussion, pursuant to Dutch Civil Code Book 2, article 108a, regarding measures to be taken, if any, since the Management Board considers it plausible that the shareholders' equity has decreased to an amount equal to or less than one-half of the paid and called up part of the capital;
11.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2016-01-11 |
除权日：
美东时间 2016-01-20 每股派息0.55美元
|
| 2015-10-13 |
除权日：
美东时间 2015-10-21 每股派息0.55美元
|
| 2015-07-07 |
除权日：
美东时间 2015-07-15 每股派息0.55美元
|
| 2015-04-13 |
除权日：
美东时间 2015-04-22 每股派息0.55美元
|
| 2015-01-12 |
除权日：
美东时间 2015-01-21 每股派息0.55美元
|
| 2014-10-06 |
除权日：
美东时间 2014-10-15 每股派息0.50美元
|
| 2014-07-08 |
除权日：
美东时间 2014-07-16 每股派息0.50美元
|
| 2014-04-14 |
除权日：
美东时间 2014-04-23 每股派息0.50美元
|
| 2014-01-13 |
除权日：
美东时间 2014-01-22 每股派息0.50美元
|
| 2013-10-08 |
除权日：
美东时间 2013-10-16 每股派息0.32美元
|
| 2013-07-09 |
除权日：
美东时间 2013-07-17 每股派息0.32美元
|
| 2013-04-15 |
除权日：
美东时间 2013-04-24 每股派息0.32美元
|
| 2013-01-11 |
除权日：
美东时间 2013-01-17 每股派息0.32美元
|
| 2012-10-09 |
除权日：
美东时间 2012-10-17 每股派息0.28美元
|
| 2012-07-10 |
除权日：
美东时间 2012-07-18 每股派息0.28美元
|
| 2012-04-16 |
除权日：
美东时间 2012-04-25 每股派息0.28美元
|
| 2012-01-13 |
除权日：
美东时间 2012-01-20 每股派息0.28美元
|
| 2011-10-11 |
除权日：
美东时间 2011-10-19 每股派息0.25美元
|
| 2011-07-12 |
除权日：
美东时间 2011-07-20 每股派息0.25美元
|
| 2011-04-18 |
除权日：
美东时间 2011-04-26 每股派息0.25美元
|
| 2011-01-14 |
除权日：
美东时间 2011-01-21 每股派息0.25美元
|
| 2010-10-12 |
除权日：
美东时间 2010-10-20 每股派息0.06美元
|
| 2010-07-12 |
除权日：
美东时间 2010-07-21 每股派息0.71美元
|